CLF065 / Scripps Research Institute, AbbVie - LARVOL DELTA

OPUS: CLF065 for Chronic Pouchitis (clinicaltrials.gov) - P2 | N=20 | Suspended | Sponsor: Calibr, a division of Scripps Research | Recruiting ➔ Suspended

Trial suspension • Gastrointestinal Disorder • Inflammation

Calibr-Skaggs Advances CLF065, a Regenerative GLP-2 Therapy, into Two Phase 2 IBD Studies (Businesswire) - "Calibr-Skaggs has enrolled the first patient in its Phase 2 study of CLF065 in chronic pouchitis and has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration for a Phase 2, 105-patient study in Crohn’s disease...The IND filing for the Phase 2 Crohn's disease study (RESET-CD) extends the program into a second IBD indication, which is expected to begin in fall 2026."

Enrollment open • IND • New P2 trial • Crohn's disease • Inflammation

OPUS: CLF065 for Chronic Pouchitis (clinicaltrials.gov) - P2 | N=20 | Recruiting | Sponsor: Calibr, a division of Scripps Research | Not yet recruiting ➔ Recruiting

Enrollment open • Gastrointestinal Disorder • Inflammation

OPUS: CLF065 for Chronic Pouchitis (clinicaltrials.gov) - P2 | N=20 | Not yet recruiting | Sponsor: Calibr, a division of Scripps Research

New P2 trial • Gastrointestinal Disorder • Inflammation